First Tracks Biotherapeutics Inc TRAXV

$19.00 0.00 (—)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$0
P/E (trailing)
—
P/E (forward)
—
Profit margin
0.00%
Debt to equity
—

Trading

Volume
400
Avg volume
—
Day's range
$19.00 – $19.14
Shares out
—
Stochastic %K
—
Beta
—
Analysts
—
Price target
—

Price

Company profile

First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and i...

Show more

First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.

Industry
Biotechnology
Sector
Healthcare
Address
10770 Wateridge Circle, Suite 210, San Diego, United States

Latest news

No headlines yet.